Syncona – building the next generation of global leaders in life science

Building a platform for long-term growth and impact

2024 annual report

Our purpose is to invest to extend and enhance human life

Watch video

Our team members are experts at what they do

Our people

A diversified portfolio of life science companies

Portfolio

To unlock the potential from truly innovative science to transform patients’ lives

We create, build and scale companies around exceptional science to create a diversified portfolio of 20-25 globally leading healthcare businesses

A diversified portfolio across clinical stages

Late-stage clinical companies

Late-stage clinical companies

Clinical companies

Clinical companies

Pre-clinical companies

Pre-clinical companies

Explore our portfolio

Introducing iOnctura

20.06.24 | Video length 5:52

Expansion of our senior team

16.01.24 | Video length 7:06

Launching Beacon Therapeutics

12.06.23 | Video length 7:36

Scaling for growth

12.12.22 | Video length 09:28

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

28.04.22 | Video length 7:43

Syncona CEO Martin Murphy discusses Clade Series A financing

03.11.21 | Video length 10:16

Anaveon doses first patient

24.06.21 | Video length 6:18

Introduction from Quell Therapeutics, CEO, Iain McGill

11.02.21 | Video length 5:38

Quell: the science and the unmet medical need for patients

11.02.21 | Video length 5:25

Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion

11.02.21 | Video length 4:25

Introducing Resolution Therapeutics

02.12.20 | Video length 11:28

Introduction to Purespring

19.11.20 | Video length 5:47

Syncona FY20: Martin Murphy discusses FY20 results

11.06.20 | Video length 6:15

Syncona FY20: Martin Murphy discusses the impact of COVID-19

11.06.20 | Video length 4:52

Syncona FY20: Martin Murphy discusses the outlook for Syncona

11.06.20 | Video length 2:53

Achilles doses first patient

29.05.20 | Video length 1:40

Gene Therapy explained

14.05.20 | Video length 3:11

Building Syncona’s Gene Therapy platform

23.10.19 | Video length 7:02

View all videos

04.09.24

A spotlight on our female leaders

20.06.24

Introducing iOnctura

27.02.24

Challenges continue but brighter days on the horizon

15.02.24

Navigating the biotech landscape: A journey from big pharma to innovative startups

25.01.24

Building a platform for the next generation of investors

16.01.24

Expansion of our senior team

08.08.23

Modality precision is the new precision in medicine

20.07.23

Taking a proactive approach to portfolio company sustainability

12.06.23

Launching Beacon Therapeutics

24.03.23

Leveraging the Syncona team for our next phase of growth

01.03.23

Good science must survive in challenging markets

12.12.22

Scaling for growth

Syncona

22.08.22

Building a global leader in retinal gene therapy

Gyroscope Therapeutics

13.07.22

Welcoming our first Windsor Fellowship intern to Syncona

28.04.22

Ed Hodgkin and Magdalena Jonikas discuss OMass Series B

03.11.21

Syncona CEO Martin Murphy discusses Clade Series A financing

Found, build, fund

24.09.21

Alex Hamilton on manufacturing in cell and gene therapy and the role of development partnerships

17.09.21

Ed Hodgkin provides his perspectives from a career in early-stage biotech

Syncona

View all insights and articles

19.11.24

Resolution Therapeutics Announces Approval of Clinical Trial Application by AEMPS to Expand Phase 1/2 EMERALD Study of RTX001 into Spain

18.11.24

Quell Therapeutics Achieves Milestone for Type 1 Diabetes CAR-Treg Cell Therapy Program

15.11.24

OMass Therapeutics Appoints Professor Steven Charlton as Chief Scientific Officer

14.11.24

Slingshot Therapeutics launches with its first programme and £12.5 million to accelerate early-stage drug development

14.11.24

Interim Results for the six months ended 30 September 2024

Syncona

11.11.24

Resolution Therapeutics Announces New Clinical and Preclinical Data Showcasing Regenerative Macrophage Therapy at AASLD 2024

08.11.24

Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel - obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)

07.11.24

Kesmalea Therapeutics Appoints Robert Johnson as CEO To Lead Development of New Class of Oral, CNS Penetrant Protein Degraders

05.11.24

Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations

31.10.24

Spur Therapeutics Publishes Preclinical Proof-of-Concept Data for SBT101, its Gene Therapy Candidate in Adrenomyeloneuropathy (AMN)

30.10.24

Anaveon announces presentation of new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

28.10.24

Purespring Therapeutics presents new preclinical data on novel gene therapy for IgA Nephropathy at ASN Kidney Week 2024

28.10.24

Autolus Therapeutics to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024

23.10.24

Spur Therapeutics Showcases Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Oral Presentation at ESGCT 31st Annual Congress

22.10.24

Quell Therapeutics to Present Promising Data from Autologous and Allogenic CAR-Treg Programs at Upcoming International Congresses

16.10.24

Autolus Therapeutics Presents Clinical Data Update at the 2024 Lymphoma, Leukemia & Myeloma Congress

15.10.24

Beacon Therapeutics Announces Positive 24-Month Data from Phase 2 SKYLINE Trial of AGTC-501 in Patients with X-Linked Retinitis Pigmentosa

09.10.24

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases

Investment team key facts

All as of 31 March 2024

12

Members of the investment team

150+

Years of life science and investment expertise

92%

Investment team with PhDs